Faith Davies MD
Hematologist-Oncologist | Hematology & Oncology
4301 W. Markham Street Mail Slot 816 Little Rock AR, 72205About
Dr. Faith Davies is a hematologist oncologist practicing in Little Rock, AR. Dr. Davies specializes in the diagnosis, treatment and prevention of blood diseases such as anemia, hemophilia, sickle-cell disease, leukemia and lymphoma. Hematologist Oncologists are also trained in the study of cancer and its attack on other organs.
Provider Details
Expert Publications
Data provided by the National Library of Medicine- Isolation and characterization of human multiple myeloma cell enriched populations.
- SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.
- Novel therapeutic targets in multiple myeloma.
- High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.
- Controversies surrounding the clonogenic origin of multiple myeloma.
- Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests.
- The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.
- Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
- Myeloma aetiology and epidemiology.
- High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
- The use of genetic microarray analysis to classify and predict prognosis in haematological malignancies.
- Proteomics and the haematologist.
- Evolving treatment strategies for myeloma.
- Haplotypes in the tumour necrosis factor region and myeloma.
- The bone marrow microenvironment influences the differential chemokine receptor
Clinical Trials
- UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus
- UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
- UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)
- UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
Faith Davies MD's Practice location
Faith Davies MD's reviews
Write ReviewRecommended Articles
- Stanford University's Linebacker Ryan Beecher Must Now Tackle Lymphoma
There's no doubt that Ryan Beecher is strong. If you want just watch one Stanford University football game, you'll see that and then some. However, he is now going to have to use a different type of strength in his battle against lymphoma.Ryan's storyWhile many had been following Ryan Beecher before...
- Treatments for Multiple Myeloma
The cancer care crew discusses what treatment will suit you after multiple myeloma has been diagnosed and staged. The following are treatments used in multiple myeloma:...
- Breaking News on the Treatment of Follicular Lymphoma
Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...
- 'Robocop' Stem Cells Developed to Fight Cancer
Cancer is the second-leading cause of death in the United States, although due to several advancements in cancer screening and treatment, survival rates have begun to improve.A new cancer therapyResearchers at the University of Minnesota and Mayo Clinic have developed a new type of cancer therapy...
- Treatment Update for Hodgkin Lymphoma
Over time, research has uncovered ways of treating Hodgkin lymphoma (HL) to produce an 80% to 90% cure rate. For the remaining 10% to 20% who are either resistant to the primary treatment or have relapsed, their cancer can still be fatal.The standard care for those not yet cured has been a two-step...
- Stem Cell Therapy Puts 4-year-old's Ultra Rare Lymphoma in Remission
4-year-old Jovon Moss was diagnosed with X-linked Lymphoproliferative Syndrome, a rare disorder of the immune system that led him to being taken back and forth to the hospital since his 3rd birthday.Jovon’s journey began in September of last year, when his mother, Brittany Fluellen, first began to...
Nearby Providers
- Dr. Sam Makhoul MD8901 Carti Way Little Rock AR 72205
- Dr. Ryan Hall M.D.8901 CARTI WAY LITTLE ROCK AR 72205
- Dr. Yazan Alsayed MD4301 W Markham St Little Rock AR 72205
- Dr. Thomas Byron Sneed M.D.8901 CARTI WAY LITTLE ROCK AR 72205
- Dr. Stella Miata Kamanda M.D.500 S University Ave Little Rock AR 72205
- Dr. Omer Khalil MD8901 CARTI WAY LITTLE ROCK AR 72205